Cybin Inc. (CYBN)
NYSEAMERICAN: CYBN · Real-Time Price · USD
6.27
-0.46 (-6.84%)
At close: Sep 8, 2025, 4:00 PM
6.27
0.00 (0.00%)
After-hours: Sep 8, 2025, 7:31 PM EDT
Cybin Employees
Cybin had 50 employees as of March 31, 2025. The number of employees did not change compared to the previous year.
Employees
50
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,934,650
Market Cap
147.97M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 50 | 0 | - |
| Mar 31, 2024 | 50 | 0 | - |
| Mar 31, 2023 | 50 | 0 | - |
| Mar 31, 2022 | 50 | 12 | 31.58% |
| Mar 31, 2021 | 38 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CYBN News
- 12 hours ago - Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder - Business Wire
- 4 days ago - Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Business Wire
- 5 days ago - Cybin to Participate in the Cantor Global Healthcare Conference 2025 - Business Wire
- 6 days ago - Cybin Announces Senior Leadership Changes - Business Wire
- 13 days ago - Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - Business Wire
- 21 days ago - Cybin Announces Results of Annual Meeting of Shareholders - Business Wire
- 26 days ago - Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results - Business Wire
- 4 weeks ago - Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - Business Wire